EDITORIAL
Optimising cancer care to improve clinical outcomes and sustainability
From chronotherapy to immunotherapy resistance, refining when and for whom treatments work is becoming central to making oncology sustainable
FROM ELCC 2026
CTLA-4 targeting leads to improved overall survival in NSCLC progressing on immunotherapy
Early phase III trial results signal a much-needed chemotherapy-free advance with gotistobart in a setting where therapeutic choices are limited
Adagrasib shows meaningful benefits in older patients with mutated NSCLC
Data reassures on targeting KRAS G12C mutations in older patients who reflect a large part of the real-world population seen in clinics
A visionary in lung oncology: the scientific and human legacy of Prof. Filippo de Marinis
A tribute from one of his former mentees, now a senior oncologist, on the occasion of the 2026 Heine H. Hansen Award presented to de Marinis
TARGETED THERAPIES
A driving force to accelerate drug development
Fostering academic clinical research is one of the ESMO’s priorities, and artificial intelligence may be a major driver
Data highlight the clinical feasibility of targeting the CD47-SIRPα axis mediating immunotherapy resistance
Early activity and manageable safety were demonstrated in two phase I trials with innovative agents
What is the way forward for undruggable tumour targets?
2026 ESMO TAT Honorary Awardee, Prof. Timothy A. Yap, sees a bright future ahead for novel synthetic lethal strategies, driven by advances in technology and novel biomarkers
OTHER NEWS
Data show how ESMO’s scales and recommendations can guide the optimisation of outcomes in patients with targetable mutations
In two studies, the use of ESCAT matching and ESMO recommendations for germline assessment lead to effective targeted treatment
Ozekibart added to chemotherapy demonstrates robust activity in relapsed/refractory Ewing sarcoma
Preliminary data on the tetravalent DR5 agonist indicate strong and durable responses with a manageable safety profile
Tailored combinations of tools are the way forward to assess quality of life in rare cancers
Recent studies emphasise that the current approach does not fully capture the needs and experiences of patients with rare tumours
OPINIONS
Overcoming resistance to immunotherapy in NSCLC?
Alessandra Curioni Fontecedro
Can the benefits of lung cancer screening be extended to never-smokers?
Joachim G. Aerts
A multimodal next-generation approach for early detection and risk stratification in lung cancer
Umberto Malapelle
Redesigning oncology clinical trials with agentic AI
Jorge Reis-Filho
From bispecific to multispecific antibodies: a highly promising field
Nina Weisser
OPINIONS
Overcoming resistance to immunotherapy in NSCLC?
Alessandra Curioni Fontecedro
Can the benefits of lung cancer screening be extended to never-smokers?
Joachim G. Aerts
A multimodal next-generation approach for early detection and risk stratification in lung cancer
Umberto Malapelle
Redesigning oncology clinical trials with agentic AI
Jorge Reis-Filho
From bispecific to multispecific antibodies: a highly promising field
Nina Weisser